



(51) International Patent Classification:

A23K 10/30 (2016.01) A23K 50/80 (2016.01)
A23K 50/30 (2016.01) C11B 9/00 (2006.01)
A23L 27/10 (2016.01) A61K 36/53 (2006.01)
A23K 50/75 (2016.01) A61K 36/54 (2006.01)

(21) International Application Number:

PCT/US2016/033271

(22) International Filing Date:

19 May 2016 (19.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/163,625 19 May 2015 (19.05.2015) US

(71) Applicant: RALCO NUTRITION, INC. [US/US]; 1600
Hahn Road, Marshall, Minnesota 56258 (US).

(72) Inventor: LAMB, Richard Dale; 201 Washington Avenue
North, Balaton, Minnesota 56115 (US).

(74) Agent: ARMITAGE, Benjamin C.; Billion & Armitage,
7401 Metro Blvd., Suite 425, Minneapolis, Minnesota
55439 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ESSENTIAL OIL COMPOSITIONS AND APPLICATIONS UTILIZING ESSENTIAL OILS

(57) Abstract: In general, embodiments of the present invention essential oil animal treatment compositions, and methods of making and using such products and compositions. The compositions comprise an essential oil fraction include including oregano essential oil, thyme essential oil, and cinnamon essential oil. The compositions can optionally include one or more emulsifiers and be in the form of an emulsion. An emulsifier can include arabinogalactan. The use of these products and compositions can enhance the health and feed efficiency of animals.



ESSENTIAL OIL COMPOSITIONS AND APPLICATIONS UTILIZING ESSENTIAL OILS

BACKGROUND

[0001] Efficient rearing of livestock and other animals is dependent upon ensuring high growth rates, feed intake, productivity, and reproductive success. Some of the greatest threats to animal growth and productivity include bacterial and fungal infections, and oxidative stress. Hormones and antibiotics are commonly used as productivity and growth promoters in animals. For example, antibiotics, such as coccidiostats, are often administered regularly in subtherapeutic doses to promote animal health and growth. However, these approaches have garnered significant outcry from scientific and social communities over the past decade.

[0002] Subtherapeutic antibiotics have been linked to pathogenic antibiotic resistance in animals, and their use as animal feed additives and growth promoters are banned in many countries. Similarly, animal hormonal supplements have been linked to detrimental side effects in animals as well as public health concerns for humans. Further, the need for alternatives to subtherapeutic antibiotics and hormonal growth promoters is readily recognized by the significant economic incentive to market animal products as “natural”, “organic”, “hormone-free” and “antibiotic-free”.

[0003] Essential oils such as oregano, thyme, and cinnamon have been disclosed in the art primarily as flavoring or odorizing agents. Essential oils have in some instances been disclosed as pharmaceuticals for medical and veterinary uses, yet the efficacy and compatibility of multi-essential oil blends are unpredictable and often undesirable. For example, U.S. Patent No.: 6,106,838 teaches that essential oils of thyme and oregano exhibit antagonist effects when combined for pharmaceutical uses.

SUMMARY

[0004] In general, embodiments of the present invention provide animal treatment compositions, and methods of making and using such products and compositions. The use of these products and compositions can act as nutritional and feed supplements to enhance the health and feed efficiency of animals.

[0005] Accordingly, embodiments of the present invention provide essential oil compositions comprising essential oils from oregano, thyme and cinnamon. Essential compositions can further include one or more emulsifiers and be in the form of an emulsion,

wherein the average particle size of the composition is less than about 25 microns. Embodiments also relate to administering the composition to animals.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006] **FIG. 1** illustrates a block flow diagram of a method of making an essential oil dispersion, according to one or more embodiments.

[0007] **FIG. 2** illustrates a block flow diagram of a method of treating a subject with an essential oil treatment composition, according to one or more embodiments.

[0008] **FIG. 3A** illustrates average daily gain data for broilers, according to one or more embodiments.

[0009] **FIG. 3B** illustrates average daily feed intake data for broilers, according to one or more embodiments.

[0010] **FIG. 3C** illustrates gain to feed data for broilers, according to one or more embodiments.

[0011] **FIG. 4A** illustrates Cobb anticipated average daily gain data for representative broilers, according to one or more embodiments.

[0012] **FIG. 4B** illustrates Cobb anticipated average daily feed intake data for representative broilers, according to one or more embodiments.

[0013] **FIG. 4C** illustrates Cobb anticipated gain to feed data for representative broilers, according to one or more embodiments.

DETAILED DESCRIPTION

[0014] This disclosure relates to essential oil compositions for use as animal supplement and feed compositions containing essential oils from oregano, thyme and cinnamon. These essential oil compositions enhance the feed efficiency and health of animals, and additionally obviate the need for products such as hormonal and/or subtherapeutic antibiotic growth promoters.

[0015] As used herein, the recited terms have the following meanings. All other terms and phrases used in this specification have their ordinary meanings as one of skill in the art would understand after review of this disclosure.

[0016] As used herein, “plants” and “plant derivatives” can refer to any portion of a growing plant, including the roots, stems, stalks, leaves, branches, seeds, flowers, fruits, and

the like. For example, cinnamon essential oil can be derived from the leaves or bark of a cinnamon plant.

[0017] As used herein, the term “essential oils” refers to aromatic, volatile liquids extracted from plant material. Essential oils are often concentrated hydrophobic liquids containing volatile aroma compounds. Essential oil chemical constituents can fall within general classes, such as terpenes (e.g., p-Cymene, limonene, sabinene, α-pinene, γ-terpinene, β-caryophyllene), terpenoids (e.g., citronellal, thymol, carvacrol, carvone, borneol) and phenylpropanoids (e.g., cinnamaldehyde, eugenol, vanillin, safrole). Essential oils can be natural (i.e., derived from plants), or synthetic.

[0018] As used herein “cinnamon essential oil” refers to one or more of natural cinnamon oil (i.e., essential oil derived from plants in the *Cinnamomum* genus), or synthetic cinnamon oil. Synthetic cinnamon essential oil can comprise synthetic cinnamaldehyde. Synthetic cinnamon essential oil can further comprise one or more major constituents of natural cinnamon essential oil. A major constituent is one which comprises at least 1 wt.%, at least 2.5 wt.%, or at least 5 wt.% of a natural essential oil assay.

[0019] As used herein “thyme essential oil” refers to one or more of natural thyme oil (i.e., essential oil derived from plants in the *Thymus* genus), or synthetic thyme oil. Synthetic thyme essential oil can comprise synthetic thymol. Synthetic thyme essential oil can further comprise one or more major constituents of natural thyme essential oil.

[0020] As used herein “oregano essential oil” refers to refers to one or more of natural oregano oil (i.e., essential oil derived from plants in the *Origanum* genus), or synthetic oregano oil. Synthetic oregano essential oil can comprise synthetic carvacrol. Synthetic oregano essential oil can further comprise one or more major constituents of natural oregano essential oil.

[0021] As used herein, the term “emulsion” refers to a fine dispersion of droplets of one liquid in which the liquid is not substantially soluble or miscible. An essential oil may be emulsified or substantially emulsified within an aqueous carrier, for example.

[0022] As used herein, the term “emulsifier” refers to a substance that stabilizes an emulsion. The emulsifier can utilize physical properties, chemical properties, or utilize both physical and chemical properties to interact with one or more substances of an emulsion. Tannic acid is an example of an emulsifier for essential oils and water.

[0023] As used herein, the term “tannin compound” refers to a polyphenolic biomolecule including at least twelve hydroxyl groups and at least five phenyl groups.

Tannin compounds include compounds utilizing gallic acid, flavone and phloroglucinol as base units. Tannic acid ($C_{76}H_{52}O_{46}$) is one form of a tannin compound. Tannic acid can include quercitannic acid and gallotannic acid, for example.

[0024] As used herein, “carrier” refers to a substance that physically binds or combines, or chemically binds or combines, with a target or active substance to facilitate the use, storage, or application of the target or active substance. Carriers are often inert materials, but can also include non-inert materials when compatible with the target or active substances. Examples of carriers include, but are not limited to, water for compositions that benefit from a liquid carrier, or diatomaceous earth for compositions that benefit from a solid carrier.

[0025] As used herein, “enzymes” refers to one or more biological molecules capable of breaking down cellulosic material. Enzymes include starch, proteins, non-starch polysaccharides, both soluble and insoluble, lignins and those biological molecules that facilitate chemical reactions within plants and animals.

[0026] As used herein, “animal” refers to all living organisms including humans.

[0027] As used herein, “poultry” refers to birds of the order Galliformes including ordinary domestic fowl or chicken (*Gallus domesticus*), turkeys (*Meleagris*), pheasants (*Phasianus*), partridges (*Perdix*), grouse (*Lagopus*), guinea fowl (*Numida*) peacocks (*Pavo*), and also birds of the order Anseriformes such as ducks (*Anas*) and geese (*Anser*).

[0028] In this disclosure, the novel utility of multi-essential oil compositions will be demonstrated. This disclosure relates to compositions including essential oils for enhancing feed efficiency and health of a subject. In many embodiments, subjects include animals. Enhancing feed efficiency can increase the growth rate, weight, weight gain rate, and nutrition of an animal. Enhanced health generally includes one or more of reduced or eliminated microbial infection, reduced or eliminated oxidative stress, reduced or eliminated infection or death during transport, reduced or eliminated microbial infection, increased body weight, enhanced egg characteristics, increased rate of weight gain, increased growth rate, reduced or eliminated birth mortality, increased or improved body score conditions, increased reproductive success, and increased gut health maturation.

[0029] Reproductive success refers to general health outcomes and effects of both the mother and the young. Maturation of the gut can include developing beneficial indigenous microflora within the gut. Enhanced egg characteristics can include one or more of increased egg size uniformity, increased egg shape uniformity, increased egg size, increased numbers

of eggs laid per clutch, increased egg clutch frequency, increased egg hatchability, increased egg shell thickness, increased egg shell thickness uniformity. Enhanced egg characteristics can be achieved in all oviparous and ovuliparous animals, which include fish, amphibians, reptiles, birds, monotremes, insects, molluscs, and arachnids. As used herein, “clutch” refers to a single period or instance of egg laying for all oviparous and ovuliparous animals.

[0030] Enhanced health can include various benefits specific to a certain class of animals. For example, enhanced health in poultry can include increased growth rate, feed efficiency, egg shell thickness and mortality rate. Enhanced health in dairy cows, or other milk-producing animals such as camels, goats, and sheep, can include increased milk production. In swine, for example, enhanced health can include a reduction or elimination of wasting diseases and mulberry heart.

[0031] Oxidative stress can include oxidative damage of tissues and cellular components, and is known to be a primary or secondary cause of many animal diseases. Oxidative stress can be measured by the concentration of reactive oxygen species (ROS) in a subject. In general, the five most damaging ROS include peroxy radicals (e.g., $R-O_2$; oxidation of polyunsaturated fatty acids by $OH^\cdot$), hydroxyl radicals ($OH^\cdot$), peroxynitrite (e.g., $ONNO^{2-}$; $H_2O_2 + NO^{2-}$), superoxide anion (e.g., $O_2^{\cdot-}$), and singlet oxygen ($^1O_2$). In animals, a variety of ROS are naturally produced through metabolic processes and by certain leukocyte populations during immune responses against disease. For example, the superoxide anion is produced by ATP synthesis. Environmental sources such as UV radiation can also increase ROS prevalence in an animal. For example, a grazing animal may have a higher singlet oxygen concentration from increased exposure to sunlight. ROS can damage cells through direct oxidation, or indirectly by inciting chemical and/or biological chain reactions which damage cells.

[0032] Antioxidants are molecules which are capable of slowing or preventing the oxidation of other molecules, and can be hydrophilic or lipophilic. Hydrophilic antioxidants can react with ROS in cell cytoplasm and blood plasma, for example. Lipophilic antioxidants can protect cell membranes from lipid peroxidation, for example. Host animals naturally produce antioxidants (e.g., glutathione, superoxide dismutase, catalase, peroxidases, uric acid, vitamin C) but stressors such as pregnancy, birthing, lactating, and accelerated growth can render natural antibiotic production inadequate for counteracting the increased ROS concentration. An increased ROS concentration can result from the host's reduced ability to produce antioxidants, a higher accumulation of ROS from natural bodily functions, a higher

accumulation of ROS from environmental factors, a higher accumulation of ROS from increased host accumulation susceptibility, and combinations thereof.

[0033] Animals are commonly administered antioxidants to counteract ROS and reduce oxidative stress, but excessive oxidative stress can diminish the efficacy of many antioxidants or create a threshold ROS level above which antioxidants are no longer effective. For example, metabolic insufficiency in an animal can prevent vitamin E or other antioxidants available in tissue and blood from counteracting ROS.

[0034] Essential oil compositions as described herein can provide antioxidant properties to a host system and generally reduce oxidative stress in animals. Essential oil compositions provided herein have high oxygen radical absorbance capacity (ORAC), which is the ability of a compound or composition to act as a proton donor and reducing agent for oxygen radicals. While many antioxidants are only effective against single ROS, the essential oil compositions provided herein have high ORAC against peroxy radicals, hydroxyl radicals, peroxynitrite, superoxide anions, and singlet oxygen, among others. Moreover, essential oil compositions provided herein comprise both lipophilic and hydrophilic characteristics which provide complete cellular protection against ROS. For example, essential oil compositions provided herein can neutralize ROS both in cytoplasm and cell walls.

[0035] The essential oil compositions as provided herein can further be used as analogous or preferable substitutes for many commercial products used today, such as coccidiostats, subtherapeutic antibiotics, growth hormones, and other similar products. As such, a financial gain is realized by those selling milk, eggs, and meat products from animals consuming the compositions provided as the products can be more readily sold as “Natural”, “Organic”, “hormone-free”, and/or “Antibiotic-Free”.

[0036] Essential oil compositions as provided herein contain essential oils derived from plants (i.e., “natural” essential oils) and additionally or alternatively their synthetic analogues. Many embodiments comprise a combination of essential oils. Some embodiments comprise a combination of natural and synthetic essential oils. In some embodiments, synthetic essential oils can be a “nature’s equivalent” synthetic blend, which generally mimics an essential oil assay of a natural essential oil by including at least 5, at least 10, at least 15, or at least 20 of the most critical essential oils within a natural essential oil. A critical essential oil can be determined by weight percent, and/or by pharmacological

efficacy. For example, a nature's equivalent synthetic oil can comprise the following constitutions as provided in Table 1:

Table 1: Nature's Equivalent Synthetic Thyme Essential Oil:

Constituent	Wt. %
Thymol	42.7-44.08
para-Cymene	26.88-27.09
Linalool	4.3-4.34
alpha-Pinene	4.1-4.26
alpha-Terpineol	3.14-3.14
1,8-Cineole	2.82-3.01
beta-Caryophellene	1.98-2.27
Limonene	1.59-1.78
delta-3-Carene	1.3-1.41
beta-Myrcene	1.26-1.31
Linalyl Acetate	1.11-1.24
beta-Pinene	1.04-1.22
Terpinen-4-ol	0.96-1.14
alpha-Caryophyllene	0.71-0.71
gamma-Terpinene	0.7-0.7
Sabinene	0.37-0.5
Borneol	0.27-0.32
Camphene	0.13-0.17

[0037] The disclosure herein indicates the efficacy of compositions comprising a plurality of essential oils which provide a synergistic effect beyond essential oils utilized in isolation. Further, essential oil compositions provided herein do not exhibit antagonistic effect between essential oil moieties within a composition. An essential oil composition generally includes an essential oil fraction and one or more additional components. The ratio of the essential oil fraction to the one or more additional components in a composition can depend on several factors such as administration method, and the nutritional/health needs and/or palate of a consuming subject, among others. In many embodiments, a consuming subject comprises an animal. Compositions can comprise additional components including carriers, emulsifiers, and stabilizers, among others. Compositions as provided herein can be in the form of an emulsion.

[0038] The essential oils present in some embodiments can include oils from the classes of terpenes, terpenoids, phenylpropenes and combinations thereof. The essential oils present in some embodiments can include oils of plants from the Labiatae or Lamiaceae family, and the Lauraceae family, including hybrids of plants from one or both families.

Suitable essential oils from the Lauraceae family can comprise those from the *Cinnamomum* genus. Within the *Cinnamomum* genus, suitable species can include *Cinnamomum burmannii*, *Cinnamomum cassia*, *Cinnamomum camphora*, *Cinnamomum loureiroi*, *Cinnamomum mercadoi*, *Cinnamomum oliveri*, *Cinnamomum osmophloeum*, *Cinnamomum ovalifolium*, *Cinnamomum parthenoxylon*, *Cinnamomum pedunculatum*, *Cinnamomum subavenium*, *Cinnamomum tamala*, *Cinnamomum verum*, *Cinnamomum verum*, and hybrids thereof.

[0039] Suitable essential oils from the Lamiaceae family can comprise those from one or more of the *Thymus* genus, the *Origanum* genus, the *Monarda* genus. Within the *Thymus* genus, a non-limiting list of suitable species can include *Thymus caespititius*, *Thymus capitatus*, *Thymus carnosus*, *Thymus citriodorus*, *Thymus glandulosus*, *Thymus Herbarana*, *Thymus hyemalis*, *Thymus integer*, *Thymus pseudolanuginosus* (formerly *T. lanuginosus*), *Thymus mastichinia*, *Thymus montanus*, *Thymus moroderi*, *Thymus pannonicus*, *Thymus praecox*, *Thymus pulegioides*, *Thymus serpyllum*, *Thymus vulgaris*, *Thymus zygis*, and hybrids thereof. Within the *Origanum* genus, a non-limiting list of suitable species can include *Origanum amanum*, *Origanum compactum*, *cordifolium*, *Origanum dictamnus*, *Origanum laevigatum*, *Origanum libanoticum*, *Origanum majorana*, *Origanum microphyllum*, *Origanum onites*, *Origanum rotundifolium*, *Origanum scabrum*, *Origanum syriacum*, *Origanum vulgare*, and hybrids thereof. Within the *Monarda* genus, a non-limiting list of suitable species can include *Monarda citriodora*, *Monarda clinopodioides*, *Monarda didyma*, *Monarda fistulosa*, *Monarda media*, *Monarda punctata*, and hybrids thereof.

[0040] The essential oils present in some embodiments can further include lavender essential oils from the *Lavandula* genus, Mexican bay leaf essential oils from the *Liteas* genus (e.g., *L. glaucescens*), West Indian bay tree essential oils from the *Pimenta* genus (e.g., *P. racemosa*), Indonesian bay leaf essential oils from the *Syzygium* genus, bay laurel essential oils from the *Laurus* genus (e.g., *L. nobilis*), California bay laurel essential oils from the *Umbellularia* genus (e.g., *U. californica*), lemon grass essential oils from the *Cymbopogon* genus (e.g., *C. ambiguous*, *C. citratus*, *C. flexuosus*, *C. martini*, *C. nardus*, *C. schoenanthus*), spearmint and peppermint essential oils from the *Mentha* genus (e.g., *M. spicata*, *M. piperita*), rosemary essential oils from the *Rosmarinus* genus (e.g., *R. officinalis*), sage essential oils from the *Salvia* genus (e.g., *S. sclarea*), hybrids thereof, and combinations thereof.

[0041] In some embodiments, an essential oil composition can include an essential oil fraction comprising three essential oils from the Lauraceae family and/or the Lamiaceae family. In some embodiments, an essential oil composition can include an essential oil fraction comprising cinnamon essential oil from the *Cinnamomum* genus, thyme essential oil from the *Thymus* genus, and oregano essential oil the *Origanum* genus. In some embodiments, an essential oil composition can include an essential oil fraction comprising synthetic cinnamaldehyde and thyme essential oils from the *Thymus* genus and oregano essential oil from the *Origanum* genus. In some embodiments, oregano essential oil can comprise carvacrol. Additionally or alternatively, thyme essential oil can comprise thymol.

[0042] In some embodiments, the essential oil fraction can comprise about 1% to about 49.5% oregano essential oil, about 1% to about 49.5% thyme essential oil, and about 1% to about 49.5% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 5% to about 47.5% oregano essential oil, about 5% to about 47.5% thyme essential oil, and about 5% to about 47.5% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 10% to about 45% oregano essential oil, about 10% to about 45% thyme essential oil, and about 10% to about 45% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 15% to about 42.5% oregano essential oil, about 15% to about 42.5% thyme essential oil, and about 15% to about 42.5% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 20% to about 40% oregano essential oil, about 20% to about 40% thyme essential oil, and about 20% to about 40% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 25% to about 37.5% oregano essential oil, about 25% to about 37.5% thyme essential oil, and about 25% to about 37.5% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 30% to about 35% oregano essential oil, about 30% to about 35% thyme essential oil, and about 30% to about 35% cinnamon essential oil. In other embodiments, the essential oil fraction can comprise about 33.33% oregano essential oil, about 33.33% thyme essential oil, and about 33.33% cinnamon essential oil.

[0043] Many essential oil compositions comprise an essential oil fraction comprising an effective amount of carvacrol, an effective amount of thymol, and an effective amount of cinnamaldehyde. In an essential oil composition including an essential oil fraction comprising oregano essential oil, thyme essential oil, and cinnamon essential oil, the essential oil fraction can comprise three or more natural essential oils wherein the combined essential

oils comprise at least an effective amount of carvacrol, at least an effective amount of thymol, and at least an effective amount of cinnamaldehyde. Suitable essential oils can include essential oils from the *Cinnamomum* genus, essential oils from the *Origanum* genus, essential oils from the *Thymus* genus, essential oils from the *Monarda* genus (e.g., *M. citriodora*, *M. clinopodioides*, *M. didyma*, *M. fistulosa*, *M. media*, *M. punctata*), essential oils from the *Trachyspermum* genus (e.g., *T. ammi*), essential oils from the *Nigella* genus (e.g., *N. sativa*), and combinations thereof. Other essential oils can be used such that effective amounts of carvacrol, thymol, and cinnamaldehyde are achieved in the essential oil fraction.

[0044] In an essential oil composition including an essential oil fraction comprising oregano essential oil, thyme essential oil, and synthetic cinnamaldehyde, the essential oil fraction can comprise two or more natural essential oils and synthetic cinnamaldehyde, wherein the combined essential oils and synthetic cinnamaldehyde comprise at an effective amount of carvacrol, at least an effective amount of thymol, and at least an effective amount of cinnamaldehyde. Suitable essential oils can include essential oils from the *Cinnamomum* genus, essential oils from the *Origanum* genus, essential oils from the *Thymus* genus, essential oils from the *Monarda* genus (e.g., *M. didyma*, and *M. fistulosa*), essential oils from the *Trachyspermum* genus (e.g., *T. ammi*), essential oils from the *Nigella* genus (e.g., *N. sativa*), and combinations thereof. Still other natural essential oils can be used such that effective amounts of carvacrol, thymol, and cinnamaldehyde are achieved in the essential oil fraction.

[0045] Some essential oil compositions comprise an essential oil fraction comprising an effective amount of carvacrol, an effective amount of thymol, and an effective amount of cinnamaldehyde. An effective amount of carvacrol can comprise at least about 10 wt.%, at least about 15 wt.%, at least about 20 wt.%, at least about 25 wt.%, at least about 30 wt.%, or at least about 33 wt.% of the essential oil fraction. An effective amount of thymol can comprise at least about 10 wt.%, at least about 15 wt.%, at least about 20 wt.%, at least about 25 wt.%, at least about 30 wt.%, or at least about 33 wt.% of the essential oil fraction. An effective amount of cinnamaldehyde can comprise at least about 10 wt.%, at least about 15 wt.%, at least about 20 wt.%, at least about 25 wt.%, at least about 30 wt.%, or at least about 33 wt.% of the essential oil fraction. In some embodiments, oregano essential oil can be replaced by one or more oils which include at least 45 wt.% carvacrol, at least 55 wt.% carvacrol, at least 65 wt.% carvacrol, or at least 75 wt.% carvacrol. In some embodiments, thyme essential oil can be replaced by one or more oils which include at least 30 wt.%

thymol, at least 35 wt.% thymol, at least 40 wt.% thymol, or at least 45 wt.% thymol. In some embodiments, cinnamon essential oil can be replaced by one or more oils which include at least 35 wt.% cinnamaldehyde, at least 40 wt.% cinnamaldehyde, at least 50 wt.% cinnamaldehyde, or at least 75 wt.% cinnamaldehyde. Suitable sources of effective amounts of carvacrol, thymol, and/or cinnamaldehyde can include natural essential oils and/or synthetic essential oils.

[0046] Essential oil compositions can further comprise one or more of an effective amount of paracymene, an effective amount of eugenol, or an effective amount of citronella. An effective amount of paracymene can comprise at least about 5 wt.%, at least about 7.5 wt.%, at least about 10 wt.%, or at least about 12.5 wt.% of the essential oil fraction. An effective amount of eugenol can comprise at least about 5 wt.%, at least about 7.5 wt.%, at least about 10 wt.%, or at least about 12.5 wt.% of the essential oil fraction. An effective amount of citronella can comprise at least about 5 wt.%, at least about 7.5 wt.%, at least about 10 wt.%, or at least about 12.5 wt.% of the essential oil fraction.

[0047] In some embodiments, the essential oil fraction comprises 100% of the essential oil composition. An essential oil composition can further comprise a carrier. Carriers are ideally inert materials which do not react with the active components (i.e., the essential oil fraction) of the composition chemically, or bind the active components physically by adsorption or absorption. Liquid carriers include water, pure water, such as reverse osmosis water, milk, milk replacers, natural and/or commercial liquid feeds, or other liquids germane to animal dietary needs. Milk replacers can be formulated to generally mimic the content of milk. For example, a milk replacer can have a composition similar to that shown in Table 2:

Table 2: Example Milk Replacer Formula

Crude Protein, minimum	22.50%
Lysine, minimum	1.60%
Crude Fat, minimum	16.50%
Crude Fiber, maximum	0.50%
Calcium, minimum	0.65%
Calcium, maximum	1.15%
Phosphorus, minimum	0.60%
Sodium, minimum	0.50%
Sodium, maximum	1.00%
Selenium, minimum	0.25 ppm
Zinc, minimum	50 ppm

[0048] The composition can be at least about 50% liquid carrier by weight, at least about 75% liquid carrier by weight, at least about 85% liquid carrier by weight, or at least about 90% liquid carrier. In some embodiments, the composition will be about 80% to about 99% liquid carrier, about 85% to about 98% liquid carrier, about 90% to about 95% liquid carrier, or about 91% to about 94% liquid carrier. In other embodiments, the composition can be about 60% liquid carrier to about 74% liquid carrier, about 63% liquid carrier to about 71% liquid carrier, about 66% liquid carrier to about 68% liquid carrier, or about 67% liquid carrier.

[0049] Solid carriers can include limestone, diatomaceous earth, and animal feed. Carriers such as limestone, diatomaceous earth, and the like, are useful pre-feed carriers in that they may be first combined with an essential oil fraction to facilitate transportation and/or subsequent combination of the essential oil composition with a dry carrier such as animal feed. Animal feed can include hay, straw, corn husks, wheat, oats, barley, seeds, commercial livestock feed, and the like. In some embodiments where an essential oil composition comprises an essential oil fraction and a pre-feed carrier, the ratio of pre-feed carrier to the essential oil fraction can be at least 10:1, at least 15:1, at least 17:1, at least 18:1, or at least 20:1. In some embodiments, where an essential oil composition comprises an essential oil fraction and a carrier, with or without a pre-feed carrier, the ratio of carrier to the essential oil fraction can be at least about 1,000:1, at least about 4,500:1, at least about 9,000:1, at least about 20,000:1, at least about 35,000:1, or at least about 50,000:1.

[0050] The total amount of carrier in a composition can be determined based on the dietary needs of an animal, the tolerance of an animal to essential oil fraction, and other factors. Tolerance can include one or more of an animal's palatability and gastrointestinal tolerance to an essential oil fraction.

[0051] An essential oil composition can further comprise one or more emulsifiers. An emulsified essential oil fraction can increase the efficacy of an essential oil composition when ingested by a subject, and can make essential oil compositions more palatable to animals which consume the compositions orally. An essential oil fraction can be combined with an emulsifier and a dry carrier, or alternatively an essential oil fraction can be combined with an emulsifier and a liquid carrier, as disclosed above, to form an emulsion. The emulsifier can be combined with an essential oil fraction in a ratio of about 3:1 to about 1:3, about 2:1 to about 1:2, about 1.5:1 to about 1:1.5, or about 1:1. An essential oil composition comprising an essential oil fraction, a liquid carrier, and an emulsifier can have an average

essential oil droplet size of less than about 25 microns, less than about 15 microns, less than about 10 microns, less than about 7.5 microns, or less than about 5 microns. In some embodiments, the average droplet size is less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, or less than about 3 microns. As used herein, “droplet size” refers to the average size of an essential oil droplet within an emulsion.

[0052] An emulsifier combined with a liquid carrier can generally be referred to as a liquid emulsifier. In some embodiments, an emulsion can comprise up to about 35%, up to about 40%, up to about 45%, or up to about 50% essential oil fraction and emulsifier, with the balance comprising a liquid carrier. In some embodiments, an emulsion can comprise less than about 20%, less than about 15%, less than about 10%, about 5%, or less than about 5% essential oil fraction and emulsifier, with the balance comprising a liquid carrier. In some embodiments, an emulsion can comprise about 40% to about 60%, or about 45% to about 55% essential oil fraction and emulsifier, with the balance comprising a liquid carrier. In some embodiments, an emulsion can comprise about 1% to about 10%, about 2.5% to about 7.5%, or about 5% essential oil fraction and emulsifier, with the balance comprising a liquid carrier. In many embodiments the liquid carrier is water. The liquid carrier content can vary depending on the amount and type of emulsifier.

[0053] One or more emulsifiers can be used to form an emulsion. In some embodiments, one or more emulsifiers can additionally or alternatively be used as a stabilizer. Stabilizers can be used to alter the viscosity of an emulsion. Altering a viscosity can include maintaining a viscosity, increasing a viscosity, or decreasing a viscosity. A suitable emulsifier can be an emulsifier capable of achieving a threshold droplet size. In some embodiments a suitable emulsifier can achieve a suitable emulsion droplet size of less than about 25 microns, less than about 15 microns, less than about 10 microns, less than about 7.5 microns, or less than about 5 microns. In other embodiments, a suitable emulsifier can achieve a suitable emulsion droplet size of less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, or less than about 3 microns. An emulsion having a droplet size below a suitable threshold enhances the efficacy of an essential oil composition.

[0054] A suitable emulsifier is larch arabinogalactan. Arabinogalactan generally comprises arabinose and galactose monosaccharides, and can be synthetic or natural. Natural arabinogalactan can be derived from plants or microbes. For example, arabinogalactan can be derived from larch trees, and many fruits, vegetables, and beans. In some embodiments,

arabinogalactan is a preferred emulsifier because it is capable of achieving a desired droplet size and also acts as an antioxidant against many ROS, including peroxy radicals, hydroxyl radicals, peroxy nitrite, superoxide anions, and singlet oxygen. Accordingly, the hydrophilic characteristics of arabinogalactan enhance the cellular coverage of an essential oil composition. A particular type of arabinogalactan is larch arabinogalactan. Other suitable emulsifiers include polydextrose, chitin, psyllium, methyl-cellulose, hydrolyzed guar, guar, soy polysaccharide, oat bran, pectin, inulin, Fructooligosaccharides (FOS), xanthan gum, alginate, chemically modified cellulosic, Acacia, and gum Arabic.

[0055] In some embodiments, a suitable emulsifier can include a tannin compound, such as tannic acid. Tannin can be used as an alternative to or in combination with the emulsifiers described above. In some embodiments, a liquid emulsifier can comprise about 100% tannic acid, about 80% to about 95% tannic acid, about 60% to about 85% tannic acid, about 40% to about 60% or about 1% to about 50% tannic acid, with the balance being a liquid carrier.

[0056] An essential oil composition can further comprise one or more dedusting agents. Dedusting agents can comprise vegetable oil, olive oil, mineral oil and the like. The amount of dedusting agent in an essential oil composition can be determined based on the amount required to keep dust low while also allowing a dry composition to be “free flowing”. A suitable “free flowing” characteristic can be determined by a funnel flow test or free flow test. A dedusting agent can be included in a feed in an amount between about 5-40lbs/ton.

[0057] **Figure 1**, illustrates a block flow diagram of a method 100 of making an essential oil composition, such as an essential oil emulsification in an aqueous carrier, is shown, according to some embodiments. One or more liquid emulsifiers are agitated 102. The one or more liquid emulsifiers are contacted 104 with one or more essential oils, sufficient to create an emulsion. The emulsion is agitated 106 while monitoring at least an emulsion temperature.

[0058] The liquid emulsifier (i.e., water and one or more emulsifiers) is agitated 102 in a vessel, such as by stirring, for a time sufficient to produce visible motion on the surface of the one or more liquid emulsifiers. The visible motion can be from the approximate surface center to one or more surface edges, at the perimeter of the vessel, for example. The time taken to reach such visible motion depends on the type of liquid emulsifier and ratio of emulsifier to water (e.g., viscosity). Once a suitable motion is established at the surface of the liquid emulsifier, one or more essential oils are added (e.g., contacted 104). The agitation

of the liquid continues and an emulsion begins to form on contact. The contact rate or addition rate should be slow enough to substantially prevent volatilization of the essential oils.

[0059] The agitation continues during the addition of the essential oils. The emulsion begins to form assuming the rate of essential oil addition is slow enough to prevent a high shear environment, adversely affecting the volatilization of the oils. Agitation 106 of the emulsion then continues until the emulsion temperature reaches about 100°F to about 110°F, about 103°F to about 108°F or about 104°F to about 107°F. As the emulsion forms, the viscosity increases. The method of agitation should be adjusted to compensate for the increase in viscosity. For example, if a stirring method is used, the stirrer or paddle should increase in force to maintain the same level of movement of the liquid as the emulsion thickens.

[0060] The final emulsion can have an average droplet size of less than about 25 microns, less than about 15 microns, less than about 10 microns or less than about 5 microns. The smaller droplet size allows for a more stable emulsion and one that previously could not be utilized for animal health or agricultural uses due to instability and high volatilization rates.

[0061] **Figure 2** illustrates a method 200 of treating a subject 230 to improve the health and/or feed efficiency of the subject, wherein the method comprises administering 220 an essential oil composition 210 to a subject. Administering 220 can include oral ingestion of the essential oil composition 210 as a feed or liquid, ingesting the essential oil composition in an encapsulated form, or applying the essential oil composition 210 topically. Pill-based or encapsulated administrations can be ideal for compositions which are not sufficiently palatable or an animal. However, administration via water or food-based carriers can be preferred for ease of administration.

[0062] A subject 230 can include all manner of animals, including poultry, horses, cows, pigs, and the like. Additionally or alternatively, subject 230 can include humans. Additionally or alternatively, subject 230 can include fish, shrimp, crustaceans, and other aquaculture. Additionally or alternatively, subject 230 can include oviparous and ovuliparous animals.

[0063] The amount of essential oil composition administered to a subject 230 can depend on the species of the subject 230, the size of the subject 10, and the health status of a subject 230. For example, essential oil compositions can be administered regularly (i.e.,

daily) as a routine nutritional and health supplement, as an intervention (i.e., for several days or for the duration of a particular episode) in response to or in conjunction with increased stress, disease, birth, or other factors, or as a one-time administration during birth or a severe infection, disease, or injury. In some embodiments, essential oil compositions 210 can be administered 220 to a subject 230 as a routine feed, in a dose of about 0.1 mg of essential oil fraction to about 10 mg of essential oil fraction per kg of subject body weight (mg/kg), about 0.25 mg/kg to about 1.1 mg/kg, about 0.5 mg/kg to about 0.75 mg/kg, or about 0.5 mg/kg. Routine feed can include water, liquid feed, and solid feeds. Essential oil compositions 210 are generally administered in an amount above 5ppm essential oil relative to the total feed dose, or approximately about 0.01 mg/kg. The dosage amount of essential oil can be varied based on the health of a subject 230. For example, an amount of essential oil per does can be increased in response to a subject 230 showing a deterioration in health, or other physical characteristic.

[0064] In some embodiments, essential oil compositions 210 can be administered 220 to a subject 230 as an intervention in a dose of about 1.0 mg/kg to about 10 mg/kg, about 2 mg/kg to about 7 mg/kg, or about 3.5 mg/kg. In some embodiments, essential oil compositions 210 can be administered 220 to a subject 230 as a one-time administration in a dose of about 10 mg/kg to about 30 mg/kg, about 13 mg/kg of essential oil fraction to about 24 mg/kg, or about 17 mg/kg.

[0065] The following Examples are intended to illustrate the above invention and should not be construed as to narrow its scope. One skilled in the art will readily recognize that the Examples suggest many other ways in which the invention could be practiced. It should be understood that numerous variations and modifications may be made while remaining within the scope of the invention.

EXAMPLE 1: Evaluation of Essential Oils in Broiler Diets

[0066] A trial was conducted to evaluate the effect of an essential oil composition in broiler chicken diets on growth performance, feed efficiency, and mortality. As used herein, “broiler” refers to chicken raised for meat. The birds were raised without stress or challenge imposed by the researchers (e.g., no heat stress, no detectable pathogen or bacterial infections, no pathogens and parasites introduced into feed, no excessive overcrowding in pens) The trial was conducted with 6 replications for each of 3 levels of feed containing an essential oil composition (SO1, containing thyme essential oil, oregano essential oil, and

cinnamaldehyde) tested against a positive control feed, Essential Oil Product C, containing thyme essential oil and oregano essential oil, and a full negative control feed containing no essential oil. The feed formulations were as follows:

1. Negative Control: pure feed (no essential oil)
2. Positive Control: 1.0 lbs. of Essential Oil Product C per 1 ton of feed
3. SO1 Low: 0.5 lbs. of SO1 per 1 ton of feed
4. SO1 Mid: 1.0 lbs. of SO1 per 1 ton of feed
5. SO1 High: 1.5 lbs. of SO1 per 1 ton of feed

[0067] Essential Oil Product C, comprises 90 wt.% carrier (~74.5 wt.% limestone, 15% wt.% diatomaceous earth), 0.5% wt.% de-dusting agent, 2.5 wt.% RO water, 2.5 wt.% commercial product Larafeed solids (Larch tree arabinogalactan), and 5 wt.% essential oil. The essential oils fraction comprises 20% thyme oil and 80% oregano oil, with a total assay of about 60.4 wt.% carvacrol, about 10.8 wt.% thymol, about 9 wt.% para-cymene, about 18.9 wt.% other secondary thyme oil and oregano oil constituents. SO1 comprises about 90 wt.% carrier (74.5 wt.% limestone, 15% wt.% diatomaceous earth), 0.5% wt.% de-dusting agent (e.g., mineral oil), 2.5 wt.% RO water, 2.5 wt.% commercial product Larafeed solids (Larch tree arabinogalactan), and 5 wt.% essential oil. The essential oils fraction comprises 33.33 wt.% thyme oil, 33.33 wt.% oregano oil, and 33.33 wt.% synthetic cinnamaldehyde, with a total assay of about 23.8 wt.% carvacrol, about 16.4 wt.% thymol, about 11.2 wt.% para-cymene, about 33.3 wt.% cinnamaldehyde about 14.6 wt.% other secondary thyme oil and oregano oil constituents.

[0068] The trial was run over 42 days with 660 1-day-old Cobb 500 cockeral broilers. The birds were wing banded, weighed, and randomly allotted to pens in one of 7 boxes on the date of delivery. Each battery brooder had 4 levels with 4 pens per level. Each level measured 3 feet wide by 4 feet long by 2 feet tall, resulting in a density of 0.545 ft²/bird. The feeding schedule was as follows:

- Days 0-16: 1.50 lbs. of feed per chick
- Days 17-26: 2.50 lbs. of feed per chick
- Days 27-36: 4.00 lbs. of feed per chick
- Days 37-42: 2.50 lbs. of feed per chick

[0069] The trial was conducted in a randomized complete block design, and data was analyzed using PROC MIXED procedure of SAS. Least squares means were separated by Fisher's Least Significant Difference. Generally, if birds are not stressed during trials, very

little difference will be observed between treatments, as to bird growth, feed intake, average daily gain, and other factors. It is worth noting, then, that even under the stress-free conditions of this trial, advantages of the SO1 formulations over the positive control (Essential Oil Product C) and negative control were still observed. Particularly, the results indicate a synergistic effect of the three-oil SO1 formulation as compared to the two-oil Essential Oil Product C formulation. Cobb data for anticipated performance of representative birds has been included to validate the trial design. Table 3 includes data for body weight, average daily gain, average daily feed intake, gain to feed, and feed to gain data for birds over the six week trial:

Table 3:

	Feed Treatment and Time					SEM	P - Value
	Control	EOP-C 1.0 lb	SO1 0.5 lb	SO1 1.0 lb	SO1 1.5 lb		
Number of pens	6	6	6	6	6		
Body Weights, g							
Initial	43.6	43.5	43.4	43.7	43.7	13.69	0.96
1st Week	161.5	161.1	162.8	162.0	163.2	13.69	
2nd Week	463.0	463.7	472.3	467.6	466.9	13.69	
3rd Week	970.2	966.8	972.3	968.1	966.2	13.69	
4th Week	1604.0	1593.3	1597.6	1583.5	1581.9	13.69	
5th Week	2273.0	2249.2	2271.9	2239.9	2224.5	13.69	
6th Week	2959.81	2913.29	2950.29	2939.04	2910.61	13.69	
Average	1210.7	1198.7	1210.1	1200.6	1193.9	5.18	0.10
ADG, g/d							
1st Week	16.58	16.73	16.80	16.83	17.16	1.71	0.93
2nd Week	42.54	42.81	43.07	43.38	43.56	1.71	
3rd Week	72.74	72.26	72.82	71.61	71.23	1.71	
4th Week	91.08	89.53	89.52	88.72	88.45	1.71	
5th Week	95.81	94.54	96.14	93.03	91.70	1.71	
6th Week	98.19	94.60	97.83	100.52	98.45	1.71	
Overall ADG	69.49	68.41	69.36	69.01	68.42	0.70	0.72
ADFI, g/d							
1st Week	29.89	29.61	30.06	28.57	28.71	3.18	0.81
2nd Week	58.05	56.04	58.38	58.07	58.58	3.18	
3rd Week	104.30	101.50	103.43	102.95	105.31	3.18	
4th Week	152.50	144.24	151.35	149.43	151.76	3.18	
5th Week	177.25	174.43	181.27	175.61	173.37	3.18	
6th Week	188.66	191.80	201.64	195.30	200.38	3.18	
Average	118.44	116.27	121.02	118.32	119.68	1.30	0.15
Gain to feed							
1st Week	0.56	0.57	0.56	0.59	0.60	0.02	0.71

2nd Week	0.73	0.77	0.74	0.75	0.74	0.02	
3rd Week	0.70	0.71	0.70	0.70	0.68	0.02	
4th Week	0.60	0.62	0.60	0.60	0.59	0.02	
5th Week	0.54	0.54	0.53	0.53	0.53	0.02	
6th Week	0.52	0.49	0.49	0.51	0.49	0.02	
Average	0.61	0.62	0.60	0.61	0.60	0.01	0.50
Feed to gain							
1st Week	1.81	1.77	1.79	1.70	1.68	0.05	0.76
2nd Week	1.37	1.31	1.36	1.34	1.35	0.05	
3rd Week	1.44	1.41	1.42	1.44	1.48	0.05	
4th Week	1.68	1.61	1.69	1.69	1.72	0.05	
5th Week	1.85	1.85	1.89	1.89	1.90	0.05	
6th Week	1.93	2.04	2.07	1.95	2.04	0.05	
Average	1.68	1.66	1.70	1.67	1.69	0.02	0.55

[0070] **Figure 3A** illustrates average daily gain data for broilers over the six trial weeks. Corresponding Cobb anticipated average daily gain data for representative broilers is illustrated in **Figure 4A**. Birds fed the SO1 Mid formulation exhibited the highest average daily gain in week 6. **Figure 3B** illustrates average daily feed intake data for broilers. Corresponding Cobb anticipated average daily feed intake data for representative broilers is illustrated in **Figure 4B**. Birds fed the SO1 Low, Mid, and High formulations all exhibited higher daily feed intakes in week 6 than birds fed either the negative or positive control. **Figure 3C** illustrates gain to feed data for broilers. Corresponding Cobb anticipated gain to feed data for representative broilers is illustrated in **Figure 4C**.

[0071] It can be seen from **Figure 3A** and Table 3 that the highest average daily gain was achieved in every week except week 4 by birds which were fed varying amounts of the SO1 formulation.

EXAMPLE 2: SO1 Diet Plan for Maximized Bird Health and Development

[0072] Strong development is critical in the early weeks of a bird's life, and accordingly a particularized feeding plan can be constructed to maximize bird health and development. Using average daily gain data from Table 3 above, the following feeding plan can be implemented under the experimental conditions described in Example 1:

1st Week: SO1 High

2nd Week: SO1 High

3rd Week: SO1 Low

4th Week: SO1 Low

5th Week: SO1 Low

6th Week: SO1 Mid

EXAMPLE 3: ORAC for Essential Oil Compositions

[0073] Table 4 illustrates the ORAC scores for oregano essential oil (*Origanum vulgare*), thyme essential oil (*Thymus vulgaris*), cinnamaldehyde, and ActiFibe (50 wt. % larch arabinogalactan, 50 wt. % water) against 5 of the most common detrimental ROS: peroxy radicals (RO_2), hydroxyl radicals ($OH^{\cdot}$), peroxyxynitrate ($ONOO^{\cdot}$; $H_2O_2 + NO_2^{\cdot}$), superoxide anion ($O_2^{\cdot-}$), and singlet oxygen (O_2). Results are expressed as trolox equivalents (TE/100g) for each composition:

Table 4: ORAC Capabilities of Essential Oil Compositions

Oxygen species	Oxygen Radical Absorbance Capacity (TE/100g)				
	Origanum vulgare	Thymus vulgaris	Cinnamaldehyde	ActiFibe	Origanum, Thymus, Cinnamaldehyde, and ActiFibe Blend
Peroxy radical	510,800	386,000	18,800	20,600	325,800
Hydroxyl radical	1,046,900	896,700	49,300	46,400	710,700
Peroxyxynitrite	5100	4,300	3,500	1,200	5,500
Superoxide anion	0	0	978,900	16,600	342,900
Singlet oxygen	361,400	207,900	90,800	11,600	231,600
Total ORAC	1,924,200	1,494,900	1,141,300	96,400	1,616,500

Table 4 illustrates that a three oil blend with ActiFibe provides high ORAC for all five ROS.

EXAMPLE 4: 3-Oil Screening Trial

[0074] 640 1-day-old Cobb 500 cockerels were wing banded, weighed and randomly assigned to pens on the day of delivery. Each pen was 3 feet wide by 2 feet long by 2 feet tall holding 10 birds each; density was 0.6 sq. ft. per bird. The pens were contained within two battery cages in a single barn, each with battery cage having 4 levels and 8 pens per level for a total of 32 pens per battery. The experimental period was 35 days divided into three (3) feeding stages, starter, grower and finisher. Bird weight, average daily gain (ADG), average daily feed intake (ADFI), feed to gain (FG) and Coccidiosis oocyte counts were determined at each period. This study was performed with a large number of treatments in order to screen a number of possible treatments for further future investigations. The treatments included (1)

a negative control (no stress, no treatment); (2) positive control, no treatment with stress (bird stress induced by administering ten times the normal level of the Advent coccidiosis vaccine in gel on top of the feed, a typical experimental broiler chick stress); (3) SO1 (75% limestone, 15% diatomaceous earth, 5% Larafeed and 5% essential oil at equal parts oregano essential oil, thyme essential oil, and cinnamaldehyde) at 0.75 pounds per ton of feed plus the cocci stress; (4) Essential Oil Product A (75% limestone, 15% diatomaceous earth, 5% Larafeed and 5% essential oil at 66.6% thyme essential oil, and 33.3% cinnamaldehyde), a combination of thyme and cinnamon oils, with the cocci stress, administered at 0.75 pounds per ton of complete feed; (5) artificial cinnamaldehyde, with the Advent vaccine cocci stress, administered at 0.75 pounds per ton; (6) Essential Oil Product B (60% Essential Oil Product C and 40% Larafeed), administered at 1.33 pounds per ton, with the Advent vaccine cocci stress; (7) Essential Oil Product C, described above, in a step-down program administered at 0.9, 0.6 and 0.4 pounds per ton in the starter, grower and finisher phases, respectively.

[0075] Average bird weights for these nine (9) treatments, from lowest to highest at thirty-five (35) days were: (a) Positive control at 1984.0 grams, as might be expected; (b) Negative control at 2039.9 grams; (c) Essential Oil Product B at 2093.1 grams; (d) Essential Oil Product C at 2153.4 grams; (e) Essential Oil Product A at 2172.0 grams; (f) cinnamaldehyde at 2180.2 grams, and (g) SO1 at 2202.4 grams. In this trial the top two treatments in bird weight performance was SO1, the 3-oil blend of oregano, thyme and cinnamaldehyde and ActiFibe, the prebiotic fiber. The positive impact of this product on gut health and host immunity led to higher feed efficiency and weight gain of all other products.

[0076] The feed-to-gain ratio (F:G) results in this trial were in the range of 1.19 to 1.26 for the starter phase, between 2.89 and 3.66 for the grower phase and 0.98 to 1.09 for the finisher phase, with lower F:G values being preferred. The 3-oil blend SO1 treatment resulted in the lowest F:G value in the starter phase at 1.19, the grower phase at 2.89, and just slightly above the lowest F:G value, 0.98, in the finisher phase at 1.00. Therefore birds that received the SO1 3-oil treatment not only grew the most, but were the most efficient in feed conversion of all the treatments in two of the three phases and next to best in the third phase. More specifically, the combination of the three oils in feed resulted in broiler birds gaining more weight and doing it more efficiently than the other two oil essential oil combinations. The SO1-treated birds also had the lowest mortality of all treatment groups.

EXAMPLE 5: 3-Oil Titration Study

[0077] 640 1-day-old Cobb 500 cockerels were wing banded, weighed and randomly assigned to pens on the day of delivery. Each pen was 3 feet wide by 2 feet long by 2 feet tall holding 10 birds each; density was 0.6 sq. ft. per bird. The pens were contained within two battery cages in a single barn, each with battery cage having 4 levels and 8 pens per level for a total of 32 pens per battery. The experimental period was 42 days divided into four feeding stages: starter, grower, finisher and withdrawal. Bird weight, average daily gain (ADG), average daily feed intake (ADFI) and gain to feed (G:F) were determined at each period. This study was performed with four treatments: three levels of SO1 against Essential Oil Product C, a two oil product, described above. This was not a challenge study, and therefore the broiler birds were not under any particular health or disease stress. The results showed that lower essential oil levels for SO1 performed the best; average treatment bird weights at day 42 were 2950.3 grams for SO1 at 0.5 pounds per ton of complete feed, 2939.0 grams at 1.0 pound per ton SO1 and 2910.6 grams at 1.5 pounds per ton SO1. This is a typical animal response to essential oils where titrations must be done to determine the best response level for the host in the environment that they are in. Birds administered Essential Oil Product C at 1 pound per ton complete feed showed an average bird weight at 42 days of 2913.3 grams, a lower weight compared to the 2950.3 grams for birds fed SO1 at 0.5 pounds per ton of complete feed. These results show that not only did the three-oil blend outperform the two oil blend, but less 3-oil blend was required in order to achieve a superior result.

EXAMPLE 5: 3-Oil Blend Challenge Against Commercial Products and Industry Standard Treatments

[0078] 640 1-day-old Cobb 500 cockerels were wing banded, weighed and randomly assigned to pens on the day of delivery. Each pen was 3 feet wide by 2 feet long by 2 feet tall holding 10 birds each; density was 0.6 sq. ft. per bird. The pens were contained within two battery cages in a single barn, each with battery cage having 4 levels and 8 pens per level for a total of 32 pens per battery. The experimental period was 42 days divided into four feeding stages: starter, grower, finisher and withdrawal. Bird weight, average daily gain (ADG), average daily feed intake (ADFI), feed to gain (FG) and Coccidiosis oocyte counts were determined at each period. This study was conducted with four treatments in order to compare Essential Oil Product C and SO1 in a challenge setting using Advent Coccidiosis vaccine at 10X the normal level, comparing it to a typical industry treatment protocol with

Coban/BMD. The treatments were (1) a positive control, no treatment with stress (bird stress induced by administering ten times the normal level of the Advent coccidiosis vaccine in gel on top of the feed, a typical experimental broiler chick stress); (2) SO1 at 1.0 pounds per ton of feed plus the cocci stress;; (3) an existing Ralco essential oil blend, Essential Oil Product C, as described above, with the cocci stress, administered at 1.0 pounds per ton of complete feed; and (4) a standard industry treatment protocol, the combination of Coban (Elanco Monensin), a drug used to prevent coccidiosis in chickens, turkey and quail with BMD (Zoetis), a type A Medicated Article for the prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry, all with the standard cocci vaccine stress with the drugs used at label directions.

[0079] Average treatment body weights of the birds at 42 days of age were: 2745.7 grams for the positive control; 2782.6 grams for SO1; 2766.1 grams for Essential Oil Product C, and 2777.8 grams for the Coban/BMD treatment. Feed-to-gain results, respectively, were 2.28, 2.45, 2.17 and 2.47. Hence, SO1 showed the greatest gain of all treatments, including the drug treatment, and further evidenced synergistic effects of the 3-oil blend.

EXAMPLE 5: Swine Finisher Trial

[0080] 1248 standard cross-bred finishing pigs from about 135 pounds to about 245 pounds were allocated to one of four treatments: (1) control with standard finishing diet; (2) control diet supplemented with 0.75 pounds per ton Essential Oil Product C; (3) control diet supplemented with 0.50 pounds per ton SO1, and (4) SO1 at 0.75 pounds per ton in the control or standard finisher diet. The pigs were house in 48 pens total and balanced for gender. At the end of each of four (4) fourteen (14) day periods the pigs were weighed and feed consumption was tracked so that in total pig weights, average daily gain (ADG), average daily feed intake (ADFI) and FCR response could be determined.

[0081] Total average individual treatment weight gains per pig over the 42 day period were: 107.2 pounds per pig for the control group; 110.6 pounds per pig for the Essential Oil Product C group; 115.0 pounds per pig for the lower level SO1 group and; 112.0 pounds per pig in the upper inclusion level SO1 group. Overall average FCR Response for the treatments in the same order were: 3.19, 3.10, 3.01 and 3.13, respectively. The best weight gain was observed in the lower level SO1 treatment (0.50 pounds per ton of complete feed) and that treatment also had the best feed conversion at feed-to-gain of 3.01. While this was a “non-

challenged” trial the pigs are in their normal finishing barn swine habitat and the superior results for SO1 demonstrated the efficacy of the 3-oil blend independent from animal species.

EXAMPLE 5: *Vibrio* in Shrimp

[0082] Several strains of the bacteria *Vibrio* are responsible for severe economic losses in commercial shrimp production worldwide. *Vibrio* causes acute hepatopancreas necrosis (AHPND) or early mortality syndrome (EMS). Antibiotics are beginning to lose efficacy against *Vibrio* and other aquaculture pathogens, in part due to an increased prevalences of resistant bacteria in the human food supply. Essential oils are here demonstrated to be an alternative to antibiotics in this application.

[0083] Three *Vibrio parahaemolyticus* strains isolated from shrimp in Mexico were used to test the efficacy of Essential Oil Product D (RO water 67.75%, Larafeed 12.75%, essential oil 18.5% and 1% TIC Gum, with the essential oil combination at 80:20 oregano oil:thyme oil) and SO1 essential oils to determine their minimum inhibitory concentrations (MIC) or the level at which the essential oils terminate the bacteria. VP 834, 276 and 696 MIC were determined using standard microbiological procedures including serial dilutions. VP 834 was isolated from shrimp stomach in Mexico, VP 276 was isolated from shrimp hepatopancreas in Mexico, and VP 696 was isolated from shrimp larva in Mexico. The results of that testing showed that the MIC of Essential Oil Product D and SO1 against 834, 276 and 696 were, in ppm, (117, 58), (234, 234) and (117, 58), respectively. Given the three strain test results, SO1 was more effective than Essential Oil Product D in two cases, and was equal to Essential Oil Product D in the other. This trial further demonstrates the synergistic benefits of the three oil blend over two oil blends.



WHAT IS CLAIMED IS

1. A composition for increasing the health and feed efficiency of an animal, the composition comprising: an essential oil fraction including oregano essential oil, thyme essential oil, cinnamon essential oil.
2. The composition of claim 1, wherein the essential oil fraction comprises about 10% to about 45% oregano essential oil, about 10% to about 45% thyme essential oil, and about 10% to about 45% cinnamon essential oil.
3. The composition of claim 1, wherein the oregano essential oil comprises oil derived from the *Origanum* genus.
4. The composition of claim 1, wherein the oregano essential oil comprises oil derived from one or more of *Origanum aamanum*, *Origanum compactum*, *cordifolium*, *Origanum dictamnus*, *Origanum laevigatum*, *Origanum libanoticum*, *Origanum majorana*, *Origanum microphyllum*, *Origanum onites*, *Origanum rotundifolium*, *Origanum scabrum*, *Origanum syriacum*, *Origanum vulgare*, and combinations thereof.
5. The composition of claim 1, wherein the oregano essential oil comprises synthetic carvacrol.
6. The composition of claim 1, wherein the oregano essential oil comprises one or more natural essential oils which collectively comprise at least 45% carvacrol.
7. The composition of claim 1, wherein the thyme essential oil comprises oil derived from the *Thymus* genus.
8. The composition of claim 1, wherein the thyme essential oil comprises oil derived from *Thymus caespititius*, *Thymus capitatus*, *Thymus carnosus*, *Thymus citriodorus*, *Thymus glandulosus*, *Thymus Herba-borana*, *Thymus hyemalis*, *Thymus integer*, *Thymus pseudolanuginosus*, *Thymus mastichinia*, *Thymus montanus*, *Thymus moroderi*, *Thymus pannonicus*, *Thymus praecox*, *Thymus pulegioides*, *Thymus serpyllum*, *Thymus vulgaris*, *Thymus zygis*, and combinations thereof.



9. The composition of claim 1, wherein the oregano essential oil comprises synthetic thymol.
10. The composition of claim 1, wherein the oregano essential oil comprises one or more natural essential oils which collectively comprise at least 30% thymol.
11. The composition of claim 1, wherein the cinnamon essential oil comprises oil derived from the *Cinnamomum* genus.
12. The composition of claim 1, wherein the cinnamon essential oil comprises oil derived from *Cinnamomum burmannii*, *Cinnamomum cassia*, *Cinnamomum camphora*, *Cinnamomum loureiroi*, *Cinnamomum mercadoi*, *Cinnamomum oliveri*, *Cinnamomum osmophloeum*, *Cinnamomum ovalifolium*, *Cinnamomum parthenoxylon*, *Cinnamomum pedunculatum*, *Cinnamomum subavenium*, *Cinnamomum tamala*, *Cinnamomum verum*, *Cinnamomum verum*, and combinations thereof.
13. The composition of claim 1, wherein the cinnamon essential oil comprises synthetic cinnamaldehyde.
14. The composition of claim 1, wherein the cinnamon essential oil comprises one or more natural essential oils which collectively comprise at least 35% cinnamaldehyde.
15. The composition of claim 1, wherein the essential oil fraction comprises three or more natural essential oils wherein the combined essential oils comprise at least 20% carvacrol, at least 15% thymol, and at least 30% cinnamaldehyde.
16. The composition of claim 1, wherein the essential oil fraction comprises two or more natural essential oils and synthetic cinnamaldehyde, wherein the combined essential oils and synthetic cinnamaldehyde comprise at least 20% carvacrol, at least 15% thymol, and at least 30% cinnamaldehyde.
17. The composition of claim 1, further comprising a carrier.

18. The composition of claim 1, further comprising an emulsifier.
19. The composition of claim 18, wherein the essential oil fraction is present as an emulsion.
20. The composition of claim 19, wherein the average droplet size of the essential oil fraction emulsion is less than about 25 microns.
21. The composition of claim 18, wherein the emulsifier comprises arabinogalactan.
22. A method of enhancing the health and feed efficiency of an animal, the method comprising:
 - administering an essential oil composition to an animal, wherein the essential oil composition comprises an essential oil fraction including oregano essential oil, thyme essential oil, cinnamon essential oil.
23. The method of claim 22, wherein the composition further comprises a carrier.
24. The method of claim 22, wherein the composition further comprises an emulsifier, and optionally a liquid carrier.
25. The method of claim 22, wherein the essential oil fraction is present as an emulsion.
26. The method of claim 25, wherein the average droplet size of the essential oil fraction emulsion is less than about 25 microns.
27. The method of claim 24, wherein the emulsifier comprises arabinogalactan.
28. The method of claim 24, wherein administering comprises one or more of oral administration or topical administration.
29. The method of claim 28, wherein oral administration can comprise ingesting the essential oil composition in one or more of a liquid form, in a solid feed form, or in an encapsulated form.



1 / 4

**FIG 1****FIG 2**



2 / 4

**FIG 3A****FIG 3B**

3 / 4

**FIG 3C****FIG 4A**

4 / 4

ADFI**FIG 4B****Feed to gain****FIG 4C**

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US2016/033271

A. CLASSIFICATION OF SUBJECT MATTER

A23K 10/30 (2016.01) A23K 50/30 (2016.01) A23L 27/10 (2016.01) A23K 50/75 (2016.01) A23K 50/80 (2016.01)
C11B 9/00 (2006.01) A61K 36/53 (2006.01) A61K 36/54 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, TXTE, CAPLUS, FSTA, BIOSIS, MEDLINE, keywords: oregano, origanum, +cinnam+, thym+, carvacrol, lamiaceae, lauraceae, emuls*, essential oils, feed, growth rate*, animal, livestock, A61K36/53/low/cn, A61K36/54/low/cn, Database Applicant/Inventor name search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 15 July 2016	Date of mailing of the international search report 15 July 2016
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au	Authorised officer Giuseppe Zagari AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. 0262833130

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2016/033271
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2014/0045692 A1 (Rossines et al.) 13 February 2014 abstract; paragraphs 1, 23, 29, 41, 107, 110-112, 122-123, 145-146, 152-155; Examples	1-29
X	GB 2503235 A (Quest Vitamins Limited) 25 December 2013 abstract; page 1, lines 18-28; pages 2-4; page 5, lines 8-22; page 6, line 16 - page 7, line 10; Formulation A page 8 onwards to claims	1-29
X	WO 2008/155536 A1 (Danisco A/S) 24 December 2008 Table 9, treatments 2/H and 3/J; Table 18; Table 19, Control and T4-T6; page page 2, line 20 - page 6, line 13; Example 3b page 28; claims 1-3, 6, 14, 15, 18; pages 54 onwards; Examples; whole document)	1-29
X	US 7429396 B2 (D'Amelio, Sr. et al.) 30 September 2008 abstract; column 2, lines 43-59; column 3, lines 5-7 and 60-67; column 4, lines 6-9, 48-50, 55-57; column 5, lines 2-8 and 38-61, column 6, lines 12-38, column 7, lines 22-60; Examples 1 and 3; claims	1-4, 6-8, 10-12, 17-18, 22-24, 28-29
X	WO 2015/047413 A1 (Furst-Mcness Company) 02 April 2015 abstract; paragraphs 1, 4, 5, 8, 9, 12, 14, 15, 30, 33, 34	1, 3-5, 7-9, 11-13, 17-19, 22-25, 28-29
X	US 2015/0004262 A1 (Kuwait Institute for Scientific Research) 01 January 2015 abstract; paragraphs 2-4, 6, 18, 20, Experiment 4 paragraph 58 and Fig. 4;	1-4, 6-8, 10-12, 17-18, 22-24, 28-29
X	WO 2015/032922 A1 (Mars, Incorporated; Mars Petcare UK) 12 March 2015 abstract; page 1, lines 1-10; page 2, lines 5-20; page 3, lines 10-26; page 8, lines 7-10; page 9, lines 4-6 and 32-34; claims	1, 3-5, 7-9, 11-13, 17-19, 21-25, 27-29
A	WO 2004/091307 A1 (Advanced Bionutrition Corporation) 28 October 2004 abstract, paragraphs 2-4, 10, 19-24, 36-41, 43-44, 46, 51, 59, 67-72	
P,X	WO 2016014699 A1 (Ralco Nutrition, Inc.) 28 January 2016 whole document; claims	1-29
P,X	WO 2016/004326 A1 (Ralco Nutrition, Inc.) 07 January 2016 whole document	1-21
P,X	US 2015/0299058 A1 (Lamb et al.) 22 October 2015 Table 8; paragraph 139	1-21

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/US2016/033271	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2014/0045692 A1	13 February 2014	US 2014045692 A1	13 Feb 2014
		CA 2827239 A1	30 Aug 2012
		EP 2678004 A1	01 Jan 2014
		JP 2014507441 A	27 Mar 2014
		WO 2012114201 A1	30 Aug 2012
GB 2503235 A	25 December 2013	GB 2503235 A	25 Dec 2013
WO 2008/155536 A1	24 December 2008	WO 2008155536 A1	24 Dec 2008
		EP 2170100 A1	07 Apr 2010
US 7429396 B2	30 September 2008	US 2006073218 A1	06 Apr 2006
		US 7429396 B2	30 Sep 2008
		US 2004213861 A1	28 Oct 2004
		US 7214392 B2	08 May 2007
		WO 2004076680 A2	10 Sep 2004
WO 2015/047413 A1	02 April 2015	WO 2015047413 A1	02 Apr 2015
US 2015/0004262 A1	01 January 2015	US 2015004262 A1	01 Jan 2015
		US 2014044812 A1	13 Feb 2014
WO 2015/032922 A1	12 March 2015	WO 2015032922 A1	12 Mar 2015
		CA 2920723 A1	12 Mar 2015
		FR 3010315 A1	13 Mar 2015
WO 2004/091307 A1	28 October 2004	None	
WO 2016014699 A1	28 January 2016	WO 2016014699 A1	28 Jan 2016
WO 2016/004326 A1	07 January 2016	WO 2016004326 A1	07 Jan 2016
		US 2016000093 A1	07 Jan 2016
US 2015/0299058 A1	22 October 2015	US 2015299058 A1	22 Oct 2015
		WO 2015161269 A1	22 Oct 2015
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			